ArticleNeoplasia (New York, N.Y.)2013

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Roberta Schmieder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.